Pålideligheden af hjertetroponiner til diagnosticering af myokardieinfarkt ved tilstedeværelse af skeletmuskelsygdom (H&M)
Hjerte og muskel undersøgelse
Visits to the emergency department (ED) for chest pain are extremely common and require a safe, rapid and efficacious treatment algorithm to exclude a possible AMI. These diagnostic algorithms are partly based on an important laboratory value, which showed growing utility in the diagnostic and prognostic of many cardiovascular diseases in the last years : cardiac troponin.
However, some patients with muscle disease often present with unexplained elevated high-sensitive cardiac Troponin T (hs-cTnT) levels in the absence of cardiac disease. The investigators aim at the characterization of the behaviour of this biomarker and its alternative (high-sensitive cardiac Troponin I), which will have important clinical implications on patients management.
Studieoversigt
Status
Status
Betingelser
Betingelser
Detaljeret beskrivelse
Introduction: The detection of cardiomyocyte injury as quantified by blood concentrations of cardiac troponin T (cTnT) or I (cTnI) is central in the diagnosis of acute myocardial infarction (AMI). While multiple cardiac disorders other than AMI may also lead to cardiomyocyte injury and therefore elevations in cTnT and cTnI, latest generations of cTnT and cTnI assays are considered to have near exclusive cardiac-specificity. Overall, both analytes (cTnT and cTnI) seem to have comparable diagnostic accuracy among patients presenting with suspected AMI to the emergency department (ED). However, their use in the diagnosis of AMI in patients with a skeletal muscle disease is questioned, as especially cTnT was found to be elevated in this setting. These increased cTnT levels have been successively attributed to a possible re-expression of cTnT isoforms in the diseased muscle, to a primary cardiac involvement associated with the muscle disease or to a cross-reaction of the hs-cTnT assay with TnT of muscle origin.
Aim: To characterize cTn levels in patients with a skeletal muscle disease to assess their utility in the field of cardiology (through their implication in AMI diagnosis and their diagnostic and prognostic accuracy regarding a possible cardiac involvement) and in the field of neurology (for the detection and risk-stratification of the muscle disorder itself).
Methodology: This study will be conducted at the University Hospital of Basel, at the Kantonsspital Aarau, both in Switzerland, and at the University Hospital of Innsbruck, Austria. A prospective cohort patient will be recruited through the neurology, rheumatology and cardiology clinics of these three hospitals. This prospective cohort of patients presenting with skeletal muscle disease will allow us to systematically screen patients for cTn increases, to investigate the prevalence and characteristics of a possible primary cardiac involvement (as documented by electrocardiogram, echocardiography, magnetic resonance imaging, cTnI, NT-proBNP (N-terminal pro-B-type Natriuretic Peptide) and any available further cardiac testing) and to explore the origins of the elevated cTn levels using muscle biopsies. Furthermore, this prospective cohort will document the role of these biomarkers in the diagnosis, prognosis and risk-stratification of the muscle disease. Patients will receive a 1- and 3-year follow-up visit with blood draw in order to measure cTn and other biomarkers and record the impact of the evolution and treatment of the muscle disease on these levels. Major adverse cardiac events including cardiovascular death, AMI, hospitalization for heart failure, and the development of clinical or subclinical heart failure as quantified by elevated blood concentrations of NT-proBNP will be recorded during follow-up.
Potential significance: Elevated cTnT levels do not only have consequences regarding the diagnosis of AMI but also raise many questions regarding their possible use as a diagnostic, prognostic and risk-stratification marker regarding the different muscle injuries and their possible primary cardiac involvement.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
-
Bern, Schweiz, 3010
- Inselspital Bern
-
-
Basel
-
Basel, Basel, Schweiz, 4056
- University Hospital Basel
-
-
Canton of Aargau
-
Aarau, Canton of Aargau, Schweiz, 5001
- Canton Hospital of Aarau
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Schweiz
- University Hospital Zürich
-
-
-
-
Innsbruck
-
Innsbruck, Innsbruck, Østrig, 6020
- Medical University Innsbruck
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Consecutive participants which have been or currently are in treatment for a muscle disease at the University hospital of Basel, at the Canton Hospital of Aarau, University Hospital of Zürich or Bern or at the Medical University of Innsbruck, or who received a new diagnosis/suspicion of such a disease will be included.
Beskrivelse
Inclusion Criteria:
- Diagnostic or suspicion of muscle disease as presence of specified keyword in patient's file or as screened by colleagues of the rheumatology, neuromuscular or other medical clinics.
- Patient consent available
Exclusion Criteria:
- Patient's refusal
- Age <18 years old
- Terminal kidney insufficiency with need for dialysis.
- Temporary exclusion criteria : Acute health condition such as myocardial infarction, patients presenting with a major trauma, a sepsis, patients shortly after cardiac surgery, and patients in shock (>100 bpm, <90 systolic BP, evidence of organ dysfunction).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Sammenligning af cTnT- og cTnI-niveauer målt ved forskellige hs-cTn-assays hos patienter med skeletmuskelsygdom.
Tidsramme: 1 år
|
1 år
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sammenligning af niveauer af cTnT og cTnI som målt ved hs-assays i matchede patienter med og uden skeletmuskelsygdom.
Tidsramme: 1 år
|
1 år
|
|
|
Regressionsmodel af forskellige patienters karakteristika på niveauer af hs-cTnI og hs-cTnT i sammenhæng med skeletmuskelsygdom versus ingen skeletmuskelsygdom.
Tidsramme: 1 år
|
1 år
|
|
|
Prognostisk værdi af hs-cTn-niveauer hos patienter med og uden skeletmuskelsygdom.
Tidsramme: 3 år
|
3 år
|
|
|
Karakterisering af cTnT og cTnI på skeletmuskelbiopsier fra myopatiske patienter.
Tidsramme: 1 år
|
1 år
|
|
|
Characterization of the impact of cTnT and cTnI on the diagnosis and prognosis of muscle diseases
Tidsramme: 3 years
|
Prognosis defined as the incidence of Major Cardiovascular Events (MACE is defined as a composite of death, acute myocardial infarction, life-threatening arrhythmia (cardiac arrest, sustained ventricular tachycardia, atrioventricular (AV) -block III), cardiac arrest/reanimation, acute heart failure (requiring admission to a hospital or intra-hospital transfer to the intensive care unit), stroke/transient ischemic attack, pulmonary embolism) |
3 years
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Forskning i udviklingen af et nyt cTnT-assay
Tidsramme: 3 år
|
3 år
|
|
Protein karakterisering
Tidsramme: 3 år
|
3 år
|
|
Hjertetroponin som prædiktorer eller screeningsværktøjer for en hjerteinvolvering
Tidsramme: 3 år
|
3 år
|
|
Hjertetroponin som prædiktor for evolution og terapeutisk respons af muskelsygdommen eller muskelregenerering.
Tidsramme: 3 år
|
3 år
|
|
Karakterisering af hjertetroponin i sygdomme af forskellige ætiologier, der involverer muskler
Tidsramme: 3 år
|
3 år
|
|
Påvirkning af muskelsymptomer på hjertetroponin
Tidsramme: 3 år
|
3 år
|
|
Hjertetroponin versus andre markører (f.eks. CK) for inflammation/nekrose af perifere muskler.
Tidsramme: 3 år
|
3 år
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Christian Mueller, MD, University Hospital, Basel, Switzerland
- Ledende efterforsker: Angelika Hammerer, MD, Canton Hospital Aarau
- Ledende efterforsker: Julia Wanschitz, MD, Medical University Innsbruck
Publikationer og nyttige links
Generelle publikationer
- Schmid J, Liesinger L, Birner-Gruenberger R, Stojakovic T, Scharnagl H, Dieplinger B, Asslaber M, Radl R, Beer M, Polacin M, Mair J, Szolar D, Berghold A, Quasthoff S, Binder JS, Rainer PP. Elevated Cardiac Troponin T in Patients With Skeletal Myopathies. J Am Coll Cardiol. 2018 Apr 10;71(14):1540-1549. doi: 10.1016/j.jacc.2018.01.070.
- Jaffe AS, Vasile VC, Milone M, Saenger AK, Olson KN, Apple FS. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol. 2011 Oct 18;58(17):1819-24. doi: 10.1016/j.jacc.2011.08.026. Epub 2011 Sep 29.
- du Fay de Lavallaz J, Prepoudis A, Wendebourg MJ, Kesenheimer E, Kyburz D, Daikeler T, Haaf P, Wanschitz J, Loscher WN, Schreiner B, Katan M, Jung HH, Maurer B, Hammerer-Lercher A, Mayr A, Gualandro DM, Acket A, Puelacher C, Boeddinghaus J, Nestelberger T, Lopez-Ayala P, Glarner N, Shrestha S, Manka R, Gawinecka J, Piscuoglio S, Gallon J, Wiedemann S, Sinnreich M, Mueller C; BASEL XII Investigators. Skeletal Muscle Disorders: A Noncardiac Source of Cardiac Troponin T. Circulation. 2022 Jun 14;145(24):1764-1779. doi: 10.1161/CIRCULATIONAHA.121.058489. Epub 2022 Apr 7.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Smerte
- Neurologiske manifestationer
- Muskuloskeletale sygdomme
- Sygdomme i nervesystemet
- Muskelhypertoni
- Neuromuskulære manifestationer
- Patologiske processer
- Patologiske Tilstande, Anatomiske
- Neuromuskulære sygdomme
- Muskuloskeletale smerter
- Atrofi
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Muskelspasticitet
- Muskelsvaghed
- Muskelsygdomme
- Muskelatrofi
- Myalgi
- Muskelkramper
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- BASEL XII
- Research Grant (Andet bevillings-/finansieringsnummer: Swiss Heart Foundation)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .